The Asian Scientist 100
Can Li
Institution
University of Hong Kong
Country
Hong Kong
Field
Engineering
Li is a recipient of the 2023 Croucher Tak Wah Mak Innovation Award for his research exploring the limitations of digital computers in performing tasks accomplished by the human brain, including recognising faces, reasoning based on vague information, and learning from experience.
(Photo: University of Hong Kong)
AWARDS
- 2023 Croucher Tak Wah Mak Innovation Award
Related articles
Gravity-Powered Lamp To Enter Field Tests
A cheap new light that could provide an alternative to kerosene and solar lamps in rural areas will enter field testing in Asia this year.
Genomic Analysis Reveals High Altitude Adaptations In A Mongolian Population
Researchers have identified genes linked to high altitude adaptations in a nomadic Mongolian population called the Deedu.
New Material For Low Cost Polymer LEDs And Solar Cells
Korean researchers have developed a new plasmonic material for low cost polymer light-emitting diode and polymer solar cell applications.
Breakthrough In Front Line Immunity Research
Researchers have characterized for the first time how interferon beta proteins bind to cells and activate an immune response.
Chinese May Have Higher Stroke Risk Than Caucasians
A new study suggests that Chinese people may have a higher risk of having a stroke than Caucasians.
Anne Likes Alex But Not Bob: What Your Name Really Says About You
Ricky van der Zwan and Anna Brooks from Southern Cross University examine how your name may influence the choices you make.
Experts: H7N9 Virus Still Cause For Concern
The H7N9 virus has several highly unusual traits that paint a disquieting picture of a pathogen that may yet lead to a pandemic, say experts.
Protagonist Therapeutics Raises $14 Million in Series B Venture Financing
The University of Queensland spin-off Protagonist Therapeutics, Inc. has completed a US$14 million Series B venture financing initiative.
Otsuka, Lundbeck Present Lu AE58054 Phase II Data For Alzheimer’s Disease
H. Lundbeck A/S and Otsuka Pharma announced Phase II clinical data on their Lu AE58054 investigational drug for moderate Alzheimer's disease.









